Watch it now!
The University of Colorado Board of Regents approved tenure appointments for two College of Engineering and Applied Science faculty:
In addition, the Regents approved the appointment of Martin Dunn as the new college dean (effective January 1, 2018), who will also join the mechanical engineering department.
Congratulations on this acheivement.
Peter Marxhausen, instructor in the Department of Civil Engineering, was awarded the National Society of Professional Engineers – Colorado 2017 College Educator of the Year. In addition to teaching at CU Denver, Marxhausen is a licensed professional engineer with Higgins & Associates Forensic Engineering Consultants and the City and County of Denver Building Department, which enables him to bring a real-world perspective to the classroom.
Congratulations on being recognized for your hard work and contributions to the college and university.
Denver (June 16, 2017) – The University of Colorado Denver announced today the appointment of Martin Dunn, Ph.D. as dean of the College of Engineering and Applied Science.
Dunn, who was hired following a national search, will succeed Marc Ingber who is stepping down after serving as dean of the College of Engineering and Applied Science (CEAS) for seven years and taking a faculty position in the Department of Mechanical Engineering. Dunn will assume the dean position in January 2018.
“Dr. Dunn will bring a new viewpoint to CEAS that directs academic scholarship toward creating and translating knowledge that broadly impacts both academia and industry,” said David Engelke, acting provost and dean of the Graduate School.
Dunn joins CEAS from Singapore University of Technology and Design (SUTD) where he is currently the associate provost for research. In this role he designs, builds and manages the research and innovation enterprise for the university. He also directs the SUTD Digital Manufacturing and Design Research Centre.
Previously, Dunn has worked for the Boeing Company, Sandia National Laboratories and the National Science Foundation. He also has held a faculty position at the University of Colorado Boulder since 1993 in the Department of Mechanical Engineering.
“The significance of universities – and in particular engineering colleges – has never been greater,” said Dunn. “At CU Denver I will champion experiential technical learning with a strong emphasis on entrepreneurial and global perspectives, holistically integrated with the development of human and social skills like creativity, teamwork, and critical thinking. The CU Denver engineering experience will be continually contemporary and allow our students to differentiate themselves and stand out in the market.”
With his extensive background in academia, government and industry, Dunn will bring a rich perspective to CEAS. He will champion contemporary experiential learning with emphasis on entrepreneurial and global perspectives. He aims to support scholarship and partnerships that create and translate knowledge to have an impact both locally and internationally.
Stephen Gedney, professor and chair of the Department of Electrical Engineering, will lead the college from July 1 until January 2018 when Dunn will begin his tenure as dean.
Daewon Park, assistant professor of bioengineering, received American Heart Association Grant-in-Aid with his research titled “Engineered biomimetic injectable system towards cardiac repair”.
Myocardial infarction (MI) is a leading ischemic cardiovascular disease. Over recent decades, the number of medical treatment methodologies for patients with MI has steadily increased, with new treatments being developed every few years. However, even with this concerted attention from the medical and research communities, a significant percentage of MI patients have suffered a recurrent attack, despite receiving proper medical treatment. There is a clear unmet need for MI treatment that prevents recurrent attacks.
With this grant, Dr. Park will develop an alternative treatment strategy, using an injectable biomaterial with the capacity for localized co-delivery of therapeutic agents, to target key endogenous processes of the post-MI healing process: the anti-inflammatory reaction and the formation of new blood vessels.
This injectable biomaterial system addresses MI in a one-time treatment platform, removing the critical barrier of patient compliance thereby promoting therapeutic success.